Impact of scheduling on toxicity and clinical efficacy of doxorubicin: What do we know in the mid-nineties?
- 1 September 1996
- journal article
- review article
- Published by Elsevier in European Journal Of Cancer
- Vol. 32 (10) , 1652-1660
- https://doi.org/10.1016/0959-8049(96)00177-3
Abstract
No abstract availableThis publication has 91 references indexed in Scilit:
- Doxorubicin weekly low dose administration: in vitro cytotoxicity generated by the typical pharmacokinetic profileEuropean Journal Of Cancer, 1992
- Doxorubicin in advanced breast cancer: Influence of schedule on response, survival and quality of lifeEuropean Journal Of Cancer, 1992
- Dose response and toxicity of doxorubicin microspheres in a rat tumor modelAnti-Cancer Drugs, 1992
- Early detection of doxorubicin cardiotoxicity: Interest of Doppler echocardiographic analysis of left ventricular filling dynamicsAmerican Heart Journal, 1989
- Doxorubicin: Effect of different schedules on toxicity and anti-tumor efficacyEuropean Journal of Cancer and Clinical Oncology, 1989
- Pharmacokinetics of weekly low dose doxorubicinEuropean Journal of Cancer and Clinical Oncology, 1989
- Doxorubicin and Methotrexate on a Weekly Schedule in Patients with SarcomasOncology, 1987
- Weekly Adriamycin versus VAC in advanced breast cancer. A randomized trialEuropean Journal of Cancer and Clinical Oncology, 1986
- Effective Treatment of Advanced Multiple Myeloma Refractory to Alkylating AgentsNew England Journal of Medicine, 1984
- Mechanism of adriamycin cardiotoxicity: Evidence for oxidative stressLife Sciences, 1981